Company Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
The company was founded in 2008 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 8, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Sean McCarthy |
Contact Details
Address: 151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 United States | |
| Phone | (650) 515-3185 |
| Website | cytomx.com |
Stock Details
| Ticker Symbol | CTMX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501989 |
| CUSIP Number | 23284F105 |
| ISIN Number | US23284F1057 |
| Employer ID | 27-3521219 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Executive Officer |
| Dr. Sean A. McCarthy DPHIL | Chairman and Chief Executive Officer |
| Dr. Marcia P. Belvin Ph.D. | Senior Vice President and Chief Scientific Officer |
| Christopher W. Ogden | Chief Financial Officer |
| Lloyd A. Rowland Jr., J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary |
| Danielle Olander-Moghadassian | Senior Vice President and Chief Human Resources Officer |
| Leslie Robbins | Senior Vice President of Intellectual Property |
| Dr. Yu-Waye Chu M.D. | Chief Medical Officer |
| Dawn Benson | Senior Vice President of Quality and Product Manufacturing |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances and Program Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |